Targeted Lymphoid Panel (TLP)
Purpose
This is a targeted sequencing assay for lymphoid neoplasms. It identifies single nucleotide variants, indels, and copy number alterations of potential significance for prognostic and therapeutic classification of lymphoid neoplasms, including ALL, B-cell lymphomas, CLL and related neoplasms.
Genes Tested (select exons)
ABL1, ARID1A, ATM, B2M, BIRC3, BRAF, BTK, CARD11, CD79B, CDKN2A, CREBBP, CRLF2, CXCR4, DNMT3A, EP300, ERG, EZH2, FOXO1, IDH2, IKZF1, IL7R, JAK1, JAK2, JAK3, KLF2, KRAS, MAP2K1, MYD88, NOTCH1, NOTCH2, NRAS, PAX5, PLCG2, RHOA, SF3B1, STAT3, STAT5B, STAT6, TET2, TNFRSF14, TP53, SH2B3, RUNX1, PTPN11, NF1, FLT3, ETV6, GATA2, PTEN, FBXW7
CPT Code
81450
Methodology
Next-generation sequencing (NGS)
Turnaround Time
21 days
Samples Tested
Blood, bone marrow, and/or extracted DNA